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Synopsis	29	
Objectives	30	
The	volume	of	prescribed	antibiotics	is	associated	with	AMR,	and	unlike	most	31	
other	antibiotic	classes,	flucloxacillin	prescribing	has	increased.	We	aimed	to	32	
describe	UK	primary	care	flucloxacillin	prescribing	and	factors	associated	with	33	
subsequent	antibiotic	prescribing	as	a	proxy	for	non-response.	34	
	35	
Patients	and	methods	36	
CPRD	patients	with	acute	prescriptions	for	oral	flucloxacillin	between	January	37	
2004	and	December	2013,	prescription	details,	associated	Read	codes	and	38	
patient	demographics	were	identified.	Monthly	prescribing	rates	were	plotted	39	
and	logistic	regression	identified	factors	associated	with	having	a	subsequent	40	
antibiotic	prescription	within	28	days.	41	
	42	
Results	43	
3,029,933	prescriptions	for	1,667,431	patients	were	identified.	Average	monthly	44	
prescription	rates	increased	from	4·70	prescriptions	per	1,000	patient-months	45	
in	2004	to	5·71	(increase	of	21·5%)	in	2013.	The	highest	prescribing	rates	and	46	
the	largest	increases	in	rates	were	seen	in	older	adults	(70+),	but	the	overall	47	
increase	in	prescribing	was	not	accounted	for	by	an	ageing	population.	48	
Prescribing	500mg	tablets/capsules	rather	than	250mg	became	more	common.	49	
Children	were	frequently	prescribed	low	dose	and	small	volumes	(5	day	course)	50	
and	prescribing	declined	for	children	including	for	impetigo.	Only	4·2%	of	new	51	
prescriptions	involved	co-prescription	of	another	antibiotic.	Age	(<5	and	≥60),	52	
diagnosis	of	‘cellulitis	or	abscess’	or	no	associated	code,	and	500mg	dose	were	53	
associated	with	a	subsequent	antibiotic	prescription,	which	occurred	after	54	
17·6%	of	first	prescriptions.	55	
	56	
Conclusions	57	
There	is	a	need	to	better	understand	the	reasons	for	increased	prescribing	of	58	
flucloxacillin	in	primary	care,	optimal	dosing	(and	the	need	to	co-prescribe	other	59	
antibiotics),	and	the	reasons	why	one	in	five	patients	are	prescribed	a	further	60	
antibiotic	within	four	weeks.	61	
62	
Introduction	63	
Flucloxacillin	is	the	most	common	narrow-spectrum	penicillinase-resistant	64	
penicillin	used	in	the	UK.	It	is	primarily	used	to	treat	infections	caused	by	65	
Staphylococcus	aureus,	and	in	the	community	use	is	almost	exclusively	for	skin	66	
and	soft-tissue	infections	(SSTI).1	Skin	conditions	are	one	of	the	commonest	67	
reasons	for	consulting	in	primary	care,	and	SSTI	are	a	common	reason	for	68	
antibiotic	prescribing	in	this	setting.	2,3	69	
	70	
Antimicrobial	resistance	is	one	of	the	most	pressing	public	health	concerns	of	71	
our	time,4	and	resistance	among	S.	aureus	to	flucloxacillin	and	other	72	
penicillinase-resistant	penicillins,	in	the	form	of	methicillin	resistant	73	
Staphylococcus	aureus	(MRSA),	is	a	key	area	of	concern.5	However,	while	many	74	
antibiotics	are	being	prescribed	less	often,	flucloxacillin	prescribing	in	UK	75	
primary	care	increased	in	the	period	up	to	2006	overall6	and	in	adults7	and	76	
children.8	Higher	volumes	of	antibiotic	prescribing	have	been	linked	to	greater	77	
levels	of	antibiotic	resistance,	both	at	the	ecological9	and	individual	patient10	78	
levels.	Therefore,	increasing	levels	of	flucloxacillin	prescribing,	particularly	if	the	79	
trend	has	continued	during	more	recent	years,	represents	an	important	source	of	80	
selection	pressure	for	the	development	of	antibiotic	resistance,	and	therefore	an	81	
important	threat	to	public	health.	However,	recent	trends	have	not	been	82	
published,	and	there	has	been	little	in	the	way	of	fine-grained	analyses	to	help	83	
understand	possible	reasons	for	the	observed	trends.	For	example,	some	84	
guidelines	recommend	co-treatment	with	phenoxymethylpenicillin	(penicillin	V)	85	
and	flucloxacillin	for	cellulitis,	particularly	when	severe	or	extensive,	11,12	86	
however	it	is	not	known	how	frequently	primary	care	clinicians	co-prescribe	87	
other	antibiotics	with	flucloxacillin.	Furthermore,	little	is	known	about	the	88	
appropriateness	of	flucloxacillin	prescribing.	The	diagnosis	of	SSTIs	can	be	89	
problematic13,	the	choice	of	antibiotic,	route,	or	dose	may	be	inappropriate,	or	90	
the	causative	organisms	may	be	resistant.	Treatment	response	is	not	routinely	91	
recorded	in	healthcare	records,	but	the	need	for	further	antibiotics	within	the	92	
next	few	weeks	can	be	used	as	a	proxy	for	treatment	non-response.		93	
	94	
Trends	in	prescribing,	particularly	when	linked	to	diagnoses	and	patient	95	
demographics,	can	be	helpful	for	clinicians,	policy	makers	and	researchers	in	96	
assessing	the	appropriateness	or	not	of	prescribing.	Therefore,	we	set	out	to:	1)	97	
describe	trends	in	prescribing	of	flucloxacillin	by	age,	gender	and	indication,	and	98	
2)	describe	patterns	of	prescribing	including	co-prescription	of	other	antibiotics,	99	
further	antibiotic	prescriptions	within	28	days	(as	a	proxy	for	non-response)	and	100	
factors	associated	with	prescribing	a	further	antibiotic	as	a	proxy	measure	for	101	
non	response	to	initial	treatment.	102	
	103	
Patients	and	methods	104	
We	analysed	data	from	the	Clinical	Practice	Research	Datalink	(CPRD)	primary	105	
care	dataset.	14	CPRD	developed	from	the	General	Practice	Research	Database	106	
(GPRD)	and	includes	one	of	the	largest	and	best	validated	primary	care	107	
databases.	The	database	contains	data	of	over	20	years	from	over	650	general	108	
practices	serving	approximately	8%	of	the	UK	population.	It	includes	anonymous	109	
data	on	patient	demographics,	prescribed	medications,	medical	(Read)	codes,	110	
consultations,	and	the	practices	contributing	to	the	database.	CPRD	conduct	111	
checks	on	data	continuity	and	completeness	and	determine	the	date	at	which	a	112	
practice	as	a	whole	is	assessed	as	providing	data	which	are	of	an	acceptable	113	
research	standard.	In	addition,	patients	are	labelled	as	‘acceptable’	for	use	in	114	
research	by	a	process	that	identifies	and	excludes	patients	with	non-contiguous	115	
follow	up	or	patients	with	poor	data	recording	that	raises	suspicion	as	to	the	116	
validity	of	the	that	patients	record.		117	
	118	
We	identified	all	patients	who	had	been	prescribed	any	oral	flucloxacillin	119	
formulation	during	the	ten-year	period	from	1	January	2004	to	31	December	120	
2013	and	were	flagged	as	having	data	of	acceptable	quality.	Prescriptions	(and	121	
any	related	medial	codes)	were	only	included	if	the	prescription	date	was	after	122	
the	date	that	the	practice	was	assessed	as	being	‘up	to	standard’	(in	terms	of	123	
research	quality	data);	after	the	date	that	the	patient	registered;	before	the	date	124	
that	the	patient	died	or	transferred	out	of	the	practice	and	before	the	date	of	the	125	
last	data	collection	from	the	practice.	Approximately	98%	of	the	population	of	126	
England	and	Wales	are	registered	with	a	GP	practice.	Prescriptions	for	127	
flucloxacillin	were	identified	based	on	product	codes	(Supplementary	web	file).	128	
	129	
Prescriptions	are	entered	on	general	practice	computer	systems	as	either	acute	130	
(single	course)	or	repeat	(a	pre-set	number	of	prescriptions	can	be	issued).	For	131	
this	analysis	only	acute	prescriptions	were	used	as	repeat	prescriptions	for	132	
flucloxacillin	are	uncommon	and	would	only	be	used	for	chronic	conditions.	133	
	134	
The	number	of	prescriptions	per	study	month	was	calculated	and	divided	by	the	135	
average	number	of	patients	registered	in	the	database	for	that	month.	We	then	136	
calculated	monthly	rates	per	1,000	registered	patients,	and	adjusted	these	for	137	
the	number	of	days	in	each	month.	Monthly	rates	were	plotted	in	a	line	graph	138	
and	we	used	a	simple	linear	regression	model,	with	month	of	year	included	as	a	139	
dummy	variable,	to	calculate	monthly	(seasonal)	effects	as	well	as	the	underlying	140	
trend.	This	analysis	used	a	data	extract	from	early	2014	and	therefore	some	141	
encounters	in	the	last	couple	of	months	of	2013	may	have	not	been	included.	142	
Therefore,	we	used	the	linear	regression	model	to	predict	prescribing	rates	for	143	
December	2013.	We	then	age-standardised	the	rates	using	the	population	data	of	144	
England	and	Wales	from	2004.15	145	
	146	
Each	prescription	was	classified	into	one	of	four	categories:	500mg	tablets	or	147	
capsules;	250mg	tablets	or	capsules;	250mg/5mL	syrup	or	suspension;	and	148	
125mg/5mL	syrup	or	suspension.	The	number	and	proportion	falling	into	each	149	
category	was	calculated	over	all	and	by	month,	and	line	graphs	used	to	display	150	
changes	over	time.	The	recorded	quantity	prescribed	was	identified.	We	151	
excluded	prescriptions	where	the	quantity	was	zero	or	so	large	that	it	was	152	
assessed	as	likely	to	be	a	coding	error.	For	tablets	or	capsules,	we	excluded	153	
quantities	>112	(the	equivalent	of	two	tablets	four	times	a	day	for	two	weeks)	154	
and	for	liquids,	where	quantities	are	usually	multiples	of	100ml,	we	excluded	155	
quantities	>2000mL	(equivalent	of	20mL	four	times	a	day	for	25	days).	The	156	
quantity	was	used	to	estimate	the	length	of	the	course	and	then	multiplied	by	the	157	
dose	to	calculate	the	total	amount	of	antibiotic	prescribed.	158	
	159	
Patient	age	(in	years)	at	the	date	of	prescription	was	calculated	and	classified	160	
into	one	of	seven	age	bands	(0-4	years,	5-9	years,	10-19	years,	20-59	years,	60-161	
79	years	and	80+	years)	for	age-specific	rates,	and	one	of	three	age-bands	(0-19	162	
years,	20-59	years	and	60+	years)	for	age	and	gender	specific	rates.	Age	and	age	163	
and	gender	specific	rates	were	calculated	as	above,	but	using	age	and	gender	164	
specific	monthly	denominator	counts.		165	
	166	
In	the	UK,	primary	care	clinicians	use	Read	codes	to	record	diagnoses,	167	
symptoms,	signs,	procedures,	etc.	To	describe	the	medical	codes	associated	with	168	
prescriptions	for	flucloxacillin,	we	identified	Read	codes	that	were	linked	by	169	
consultation	ID	number.	We	searched	for	2051	Read	codes	that	could	potentially	170	
indicate	an	SSTI.	As	we	only	included	consultations	in	which	flucloxacillin	had	171	
been	prescribed,	we	used	an	inclusive	approach,	including	for	example	‘breast	172	
lump’	as	being	indicative	of	a	breast	infection,	‘eczema’	as	being	indicative	of	173	
infected	eczema	and	‘dressing	change’	as	being	indicative	of	a	wound	infection.	174	
We	included	281	codes	for	SSTI	diagnoses	(cellulitis,	abscess,	impetigo,	175	
folliculitis,	etc.),	42	codes	for	ingrowing	nails,	paronychia	and	other	digital	176	
infections,	215	codes	for	breast,	head	and	neck,	bursitis,	umbilicus	and	limb	177	
infections,	884	codes	for	insect	bites,	other	bites,	traumatic	wounds	and	post-178	
operative	wounds,	524	codes	for	skin	conditions	that	may	become	secondarily	179	
infected	(eczema,	seborrhoeic	and	contact	dermatitis,	psoriasis,	viral	or	fungal	180	
infections,	skin	ulcers,	cysts,	warts,	naevi,	blisters,	etc.),	29	codes	for	non-specific	181	
‘skin	and	soft-tissue	infection’,	rash,	and	‘skin	symptoms’,	and	76		codes	for	other	182	
skin	conditions	(erythrasma,	phlebitis,	thrombophlebitis,	varicose	veins,	183	
pyoderma,	acne,	rosacea).	Theses	were	then	classified	into	one	of	the	following	184	
classifications:	cellulitis	or	abscess,	impetigo,	boils/folliculitis,	infected	185	
finger/toe,	infection	of	other	skin	region,	infected	trauma/wound,	secondary	186	
infection	of	skin	lesion,	non-specific	SSTI,	and	other	skin	infection.	We	also	187	
searched	for	Read	codes	for	respiratory	tract	infections,	urinary	tract	infections,	188	
and	osteomyelitis.	Consultations	with	none	of	the	above	codes	were	then	189	
classified	as	having,	‘no	relevant	code’	or	no	Read	code.	The	Read	codes	used	are	190	
included	as	supplementary	material.	We	then	calculated	the	proportion	of	191	
prescriptions	that	were	classified	into	each	category,	and	the	three	main	sub-192	
categories	for	each	major	category.	We	also	calculated	monthly	rates	for	each	193	
category	of	SSTI	and	plotted	these	as	a	line	graph.		194	
	195	
We	identified	all	antibiotic	prescriptions	that	occurred	over	the	ten-year	study	196	
period	for	all	patients	that	had	received	one	or	more	prescription	for	197	
flucloxacillin.	We	then	identified	all	first	prescriptions	of	flucloxacillin	(those	that	198	
did	not	have	another	flucloxacillin	prescription	in	the	preceding	28	days),	and	199	
then	whether	any	additional	antibiotics	were	co-prescribed	at	the	same	time	or	200	
in	the	following	28	days.	Prescriptions	are	not	directly	linked	to	a	diagnosis	in	201	
CPRD	(but	may	be	linked	to	Read	codes	via	a	consultation	ID	number)	and	202	
therefore	we	took	a	pragmatic	approach	of	including	only	prescriptions	within	203	
the	first	four	weeks	as	being	likely	to	be	related	to	the	same	condition.	Where	204	
subsequent	antibiotics	were	prescribed,	we	classified	all	subsequent	antibiotic	205	
prescriptions	that	occurred	within	28	days	of	each	other	as	part	of	the	same	206	
‘episode’.	We	then	calculated	the	amount	of	time	each	patient	was	included	in	the	207	
database	by	taking	a	start	date	as	the	latter	or	1	January	2004,	the	date	they	first	208	
registered	with	the	practice	or	the	date	the	practice	was	assessed	as	being	up	to	209	
standard,	and	the	end	date	as	the	earlier	of	31	December	2013,	the	date	the	210	
patient	transferred	out	of	the	practice,	the	date	the	patient	died,	or	the	last	data	211	
collection	date	for	the	practice.	Patients	with	<90	days	of	observation	were	212	
excluded	and	then	the	number	of	episodes	per	year	of	observation	was	213	
calculated	and	converted	to	number	per	10	years.		214	
	215	
To	identify	factors	associated	with	receiving	a	subsequent	prescription	of	an	216	
antibiotic	that	might	be	used	for	a	SSTI	(oral	penicillin,	macrolide,	tetracycline,	217	
cephalosporin,	metronidazole,	quinolone,	clindamycin,	sodium	fusidate	or	218	
vancomycin)	we	used	logistic	regression.	Patient	age,	gender,	diagnostic	219	
category,	dose	formulation,	study	year	and	an	interaction	between	study	year	220	
and	formulation	(to	determine	whether	changes	in	dose/formulation	over	time	221	
were	associated	with	having	a	subsequent	antibiotic)	(as	a	proxy	for	potential	222	
treatment	failure).	223	
	224	
The	study	funder	reviewed	the	study	proposal	but	played	no	role	in	the	study	225	
design;	in	the	collection,	analysis,	and	interpretation	of	the	data;	or	in	the	writing	226	
of	the	report.	227	
	228	
This	study	was	approved	by	the	Independent	Scientific	Advisory	Committee	(Ref:	229	
14_096),	the	independent	body	that	approves	use	of	CPRD	data.	230	
Results	231	
We	identified	1,678,403	patients	that	received	3,114,366	prescriptions	for	232	
flucloxacillin	in	3,110,348	consultations	over	the	ten-year	period.	A	total	of	233	
82,399	(2·65%)	prescriptions	that	were	identified	as	being	‘repeat	prescriptions’	234	
and	1418	(0·05%)	prescriptions	with	dates	that	did	not	match	the	consultation	235	
date	were	removed	from	further	analysis,	leaving	3,031,179	prescriptions	issued	236	
to	1,667,431	patients	in	3,029,933	consultations.		237	
	238	
Monthly	prescription	rates	with	a	monthly	linear	regression	line	are	shown	in	239	
figure	1.	The	average	monthly	rates	for	each	year	are	presented	in	Table	1.	Over	240	
the	ten-year	period	from	2004	–	2013	prescribing	for	flucloxacillin	increased	by	241	
21·1%	((5·74	-	4·74)/4·74).	There	was	significant	seasonal	variation	with	the	242	
highest	prescribing	rates	in	the	summer	months	and	the	lowest	rates	in	the	243	
winter,	and	an	overall	trend	of	increasing	prescribing	over	the	study	period.	The	244	
relative	influence	of	month	of	the	year	is	shown	in	the	regression	analysis	in	245	
Table	2.	The	lowest	prescription	rate	was	in	December	and	the	highest	was	in	246	
July,	which	had	a	coefficient	of	1·61	(95%	CI:	1·35,	1·87),	which	equates	to	a	33%	247	
increase	compared	to	December	(using	the	December	2008	rate	(4·82)	as	the	248	
baseline).			249	
	250	
There	were	marked	differences	in	prescribing	rates	by	age	band	(Figure	2).	The	251	
highest	prescribing	rates	were	in	the	over	70’s,	with	a	gradual	increase	in	252	
prescribing	rates	over	the	ten-year	period	in	the	70-79	and	80+	age	bands,	a	253	
slight	increase	in	the	60-69s,	and	slight	reduction	in	5-9	year	olds.	Prescribing	254	
rates	by	gender	were	similar	for	children	(0-19)	and	older	adults	(60+)	but	for	255	
the	20-59	year	age	band	prescribing	rates	were	consistently	higher	for	women	256	
than	men	(Figure	3).	257	
	258	
The	majority	(87·2%)	of	prescriptions	were	of	tablets	or	capsules	as	opposed	to	259	
suspensions	or	syrups.	Over	the	ten-year	period	there	was	a	substantial	shift	260	
from	prescribing	predominantly	250mg	tablets	or	capsules	to	prescribing	261	
predominantly	500mg	tablets	or	capsules	(Figure	4).	A	total	of	2,688	(0.09%)	262	
prescriptions	were	recoded	as	missing	for	the	analysis	of	quantity	because	the	263	
quantities	were	over	112	(for	tablets	or	capsules)	or	2000mL	(for	liquids).	264	
Overall,	80.8%	of	all	tablet/capsule	prescriptions	were	for	28	tablets/capsules,	265	
which	equates	to	a	seven-day	course.	Ten	percent	were	for	<28	and	9.2%	were	266	
for	>28.	There	was	no	significant	variation	in	the	quantity	prescribed	across	267	
adult	age	groups	or	by	study	year.	As	such,	the	shift	in	total	amount	of	268	
flucloxacillin	prescribed	in	each	course	increased	for	all	adult	age	groups	during	269	
the	period	under	study.	For	liquid	preparations,	76.9%	of	prescriptions	were	for	270	
100mL,	which	is	equivalent	to	a	5	day	course	of	a	5mL	dose	four	times	a	day,	271	
with	1.5%	being	for	<100mL	and	21.6%	being	for	>100mL.	The	total	amount	of	272	
antibiotic	prescribed	for	children	by	age	bands	is	shown	in	Table	3.	No	change	273	
was	seen	over	the	ten-year	period	in	the	total	amount	of	antibiotic	prescribed	274	
per	course	for	younger	children,	but	a	small	increase	was	seen	in	10-19	year	275	
olds.	276	
	277	
A	wide	range	of	Read	codes	were	associated	with	consultations	in	which	278	
flucloxacillin	was	prescribed.	Consultations	were	classified	into	1	of	12	broad	279	
categories	(including	‘No	code’),	and	these,	along	with	the	most	frequent	280	
diagnoses	within	each	category,	are	presented	in	Table	4.	The	most	frequent	281	
category	(‘No	relevant	code’)	represents	consultations	in	which	one	or	more	282	
Read	code	was	used,	but	there	are	no	codes	that	give	any	indication	of	an	283	
infection	or	any	other	likely	reason	for	prescribing	flucloxacillin.	When	this	284	
category	is	combined	with	those	with	no	code	at	all,	one	third	of	all	prescriptions	285	
were	not	associated	with	any	codes	that	indicated	(or	suggested)	a	diagnosis.	286	
The	most	frequent	diagnostic	categories	were	cellulitis	or	abscess	(10·0%),	287	
secondary	infection	of	skin	condition	(10·0%),	non-specific	SSTI	(9·7%)	and	288	
infected	trauma/wound	(9·1%).	A	very	small	proportion	(0·3%)	of	prescriptions	289	
had	codes	for	infections	of	other	systems	(osteomyelitis,	urinary	tract	infections	290	
or	respiratory	tract	infections)	associated	with	them.	Trends	in	the	frequency	of	291	
SSTI	categories	over	time	are	presented	in	Figure	5.	The	most	remarkable	292	
features	are	the	marked	seasonality	for	traumatic	(primarily	insect	bite)	293	
infections	and	the	gradual	decline	in	flucloxacillin	prescribing	for	impetigo.	294	
	295	
A	total	of	2,888,777	first	(with	no	antibiotic	prescription	in	the	preceding	28	296	
days)	prescriptions	of	flucloxacillin	were	identified	in	1,678,183	patients;	3670	297	
patients	were	removed	because	they	contributed	<90	days	of	data,	leaving	298	
2,766,006	episodes	of	care	(series	of	prescriptions	with	28	days	or	less	between	299	
them)	in	1,674,513	patients.	A	total	of	486,432	(17·6%)	first	prescriptions	were	300	
followed	by	a	subsequent	prescription	antibiotic	prescription	within	28	days,	301	
and	of	these,	126,955	(4·6%	of	total)	involved	further	subsequent	antibiotics,	302	
resulting	in	episodes	that	involved	three	or	more	prescriptions.	See	Table	5.	303	
There	was	a	median	(IQR)	of	2·0	(1·0,	3·0)	episodes	per	patient	per	10	years.		304	
	305	
Only	115,959	(4·2%)	of	2,766,006	first	prescriptions	had	co-antibiotics	(in	306	
addition	to	flucloxacillin)	prescribed	during	the	same	consultation.	The	most	307	
common	co-antibiotics	were	penicillin	V	(58·6%),	amoxicillin	(14·4%),	308	
metronidazole	(12·6%),	co-amoxiclav	(3·2%),	and	erythromycin	(1·9%).	The	309	
most	frequently	reported	antibiotics	prescribed	at	subsequent	consultations	310	
(that	involved	prescription	of	any	antibiotic)	were	flucloxacillin	(44·6%),	co-311	
amoxiclav	(10·2%),	erythromycin	(8·9%),	amoxicillin	(8·1%)	and	penicillin	V	312	
(6·7%).	313	
	314	
Young	(0-4	years)	and	older	(60+)	age	(compared	to	the	reference	category	of	315	
20-59	years),	having	a	diagnosis	of	cellulitis	of	abscess	or	having	no	Read	code	316	
(compared	to	having	a	code	that	did	not	indicate	an	infection)	and	being	317	
prescribed	500mg	tablets	(compared	to	250mg	tablets)	were	all	associated	with	318	
a	10%	or	more	increase	in	the	odds	of	having	a	subsequent	antibiotic	319	
prescription	within	the	next	28	days	(Table	6).		Having	a	diagnosis	of	boils	/	320	
folliculitis	or	‘infection	at	other	site’		(mostly	breast	infection	or	otitis	externa)	321	
was	associated	with	a	10%	or	more	reduction	in	the	odds	of	having	a	subsequent	322	
antibiotic	prescription,	when	compared	to	having	no	relevant	diagnostic	code.	323	
There	was	no	significant	(in	terms	of	size	of	effect)	association	with	time	(year)	324	
and	no	significant	interaction	between	dose	and	time	(year).	325	
Discussion	326	
The	prescription	rate	for	flucloxacillin	in	primary	care	in	the	UK	increased	by	327	
21·1%	between	2004-2013,	with	marked	peaks	in	the	summer.	Over	the	same	328	
time	period	there	was	a	marked	shift	toward	prescribing	higher	dose	(500mg	329	
tablets)	over	low	dose	(250mg	tablets)	flucloxacillin.	The	highest	prescribing	330	
rates	and	the	largest	increases	in	rates	were	seen	in	older	adults	(70+).	There	331	
were	few	differences	by	gender.	The	quantity/duration	of	antibiotics	prescribed	332	
(typically	7	days	for	tablets	and	5	days	for	liquid)	did	not	change	significantly,	333	
and	therefore	the	increasing	use	of	higher	dose	tablets	led	to	an	increase	in	the	334	
average	total	amount	of	antibiotic	prescribed	between	2004	and	2013	for	adults.	335	
Many	children	were	prescribed	lower	doses	than	recommended	for	their	age	(for	336	
example,	one	third	of	8-10	year	olds	were	prescribed	the	equivalent	of	125mg	4	337	
times	a	day	for	5	days	or	less.	Cellulitis	or	abscess,	secondary	infection	of	skin	338	
conditions	and	infected	trauma/wound	were	the	most	prevalent	diagnostic	339	
categories.	However,	over	a	third	of	prescriptions	had	no	associated	relevant	340	
medical	diagnostic	code	and	a	further	10%	were	associated	with	a	non-specific	341	
SSTI	code.	Most	(82·4%)	new	prescriptions	for	flucloxacillin	were	not	followed	342	
by	an	antibiotic	prescription	within	the	next	28	days.	There	was	a	median	of	2	343	
(IQR	1,	3)	episodes	(clusters	of	antibiotic	prescriptions	within	28	days	of	each	344	
other	that	started	with	a	prescription	of	flucloxacillin)	per	10	years	per	patient.	345	
Being	under	5	or	over	60,	having	a	diagnostic	code	for	cellulitis	or	abscess	or	no	346	
diagnostic	code,	and	being	prescribed	higher	dose	flucloxacillin,	were	all	347	
associated	with	an	increased	odds	of	being	prescribed	an	antibiotic	in	the	28	348	
days	following	an	initial	flucloxacillin	prescription.	Only	4·2%	of	first	349	
prescriptions	of	flucloxacillin	had	another	antibiotic	prescribed	at	the	same	time,	350	
and	58·6%	of	these	were	penicillin	V.	351	
	352	
This	study	used	a	large,	well-validated	database	with	research-quality	data.16	By	353	
using	data	going	back	to	2004	we	were	able	to	examine	trends	over	time,	and	by	354	
using	such	a	large	dataset,	we	were	able	to	describe	precisely	the	rates	by	month	355	
(and	therefore	describe	the	seasonality	of	use)	and	by	important	sub-groups.	356	
Prescriptions	in	UK	general	practice	are	almost	universally	generated	via	the	357	
computer,	and	therefore	recording	of	prescribing	data	is	very	accurate.	However,	358	
it	is	possible	that	some	prescriptions,	particularly	those	generated	during	home	359	
visits,	will	not	be	included.	Home	visits	are	a	small	proportion	of	the	workload,	360	
particularly	for	a	condition	that	does	not	often	incapacitate	(SSTIs),	but	it	is	361	
possible	that	housebound	patients,	who	are	at	risk	of	cellulitis,	are	under-362	
represented.	363	
	364	
The	main	weakness	of	this	study	is	that	prescriptions	are	not	directly	linked	to	365	
diagnosis	in	CPRD.	Linking	of	diagnostic	codes	can	only	be	achieved	at	the	level	366	
of	the	consultation	(i.e.	Read	codes	entered	during	the	same	consultation	in	367	
which	a	prescription	is	issued	are	likely	to	be	linked).	However,	we	found	that	368	
even	at	the	consultation	level	a	high	proportion	of	prescriptions	had	no	369	
associated	diagnostic	codes.	There	are	also	few	data	available	to	measure	the	370	
accuracy	of	the	diagnostic	codes	used,	and	given	the	large	number	of	codes	371	
within	the	Read	system,	there	will	inevitably	be	variations	in	coding	practices	372	
between	GPs.	Fortunately,	flucloxacillin	is	an	antibiotic	that	is	only	indicated	for	373	
infections	likely	to	be	caused	by	Staphylococcus	aureus,	and	in	UK	primary	care	374	
this	is	almost	exclusively	SSTI.	Therefore,	we	can	have	confidence	in	the	overall	375	
levels	of	prescribing	being	robust,	but	the	subdivision	by	diagnoses	may	need	to	376	
be	treated	with	caution.	In	our	analysis	of	subsequent	prescribing,	we	identified	377	
prescriptions	for	any	antibiotic	that	could	be	used	for	SSTI,	and	did	not	limit	378	
inclusion	to	those	that	were	associated	with	an	SSTI	code.	It	is	possible	that	some	379	
of	these	prescriptions	were	for	alternative	(new)	diagnoses,	such	as	respiratory	380	
tract	infections,	however	we	restricted	the	follow-up	period	to	four	weeks,	and	381	
found	that	the	most	commonly	prescribed	subsequent	antibiotic	was	also	382	
flucloxacillin.	Therefore,	we	believe	that	we	are	predominantly	identifying	383	
subsequent	prescribing	for	SSTIs.	384	
	385	
Previous	analyses	of	flucloxacillin	prescribing	in	primary	care	have	shown	rates	386	
increasing	up	to	2006,	6-8	and	we	were	able	to	demonstrate	that	this	trend	387	
continued	up	to	the	end	of	2013,	and	that	increases	were	primarily	in	older	388	
adults.	We	used	age-specific	population	denominators	and	the	rates	have	been	389	
age-standardised	to	the	2004	population	of	England	and	Wales,	and	so	the	390	
increases	do	not	simply	relate	to	an	ageing	population.	However,	the	changes	in	391	
population	demographics,	with	significant	on	going	increases	in	the	proportion	392	
of	the	population	that	are	older,	do	make	these	data	particularly	concerning	and	393	
worthy	of	further	investigation.			394	
	395	
One	obvious	question	is	whether	the	increase	in	flucloxacillin	prescribing	is	396	
caused	by	an	increase	in	the	incidence	of	consultations	for	SSTI,	or	if	it	relates	to	397	
a	reduction	in	the	threshold	for	prescribing.	We	recently	identified	SSTIs	as	a	398	
common	infection	and	a	common	reason	for	antibiotic	prescription	in	older	399	
adults	in	care	homes.17	However,	data	on	how	the	incidence	of	SSTIs	in	this	age	400	
group	has	changed	over	time	is	somewhat	conflicting.	Fleming	reported	401	
reductions	in	the	incidence	of	skin	infections	in	primary	care	for	both	adults	and	402	
children	between	1999	and	2005,7	but	did	not	look	specifically	at	older	adults.	403	
Hayward,	on	the	other	hand,	used	Hospital	Episode	Statistics	(HES)	data	to	404	
explore	trends	in	hospital	admissions	for	community-onset	staphylococcal	405	
diseases,	and	found	an	increase	between	1989/90	and	2003/4,	with	the	highest	406	
rates,	and	greatest	increases,	in	older	adults.6		407	
	408	
Although	any	trend	toward	increased	antibiotic	prescribing	is	potentially	409	
concerning,	the	implications	of	increasing	flucloxacillin	prescribing	on	410	
antimicrobial	resistance	(in	the	form	of	MRSA)	are	unclear.	A	recent	study	of	the	411	
prevalence	of	MRSA	in	commensals	identified	from	the	anterior	nares	of	412	
individuals	in	the	community	found	low	levels	in	all	nine	European	countries	413	
studied	(including	the	UK).18	414	
	415	
We	were	not	able	to	identify	any	other	studies	that	highlighted	the	shift	from	416	
prescribing	lower-dose	to	higher-dose	flucloxacillin	over	the	past	decade.	The	417	
higher	dose	is	certainly	recommended	for	cellulitis	or	other	infections	where	418	
Group	A	Streptococci	are	the	likely	causative	organisms.	However,	there	remains	419	
little	empirical	evidence	to	guide	the	dose	or	duration	of	treatment.	The	use	of	420	
lower	than	recommended	unit	doses	for	flucloxacillin	in	children	has	been	421	
previously	described19	but	we	took	this	further	by	identifying	that	most	children	422	
are	prescribed	only	enough	for	5	days.	As	with	adults,	there	is	little	empirical	423	
evidence	supporting	an	optimal	dose	or	duration.	However,	our	data	make	it	424	
apparent	that	children	are	frequently	prescribed	low	doses	and	short	courses.	425	
	426	
We	found	that	nearly	one	in	five	patients	who	are	prescribed	a	course	of	427	
flucloxacillin	are	prescribed	a	subsequent	course	of	antibiotics	within	four	428	
weeks,	suggesting	that	treatment	failure	may	be	a	significant	problem.	Currie	429	
and	colleagues	reported	a	treatment	failure	rate	for	SSTIs,	using	a	similar	430	
approach	but	identifying	consultations	where	any	antibiotic	was	associated	with	431	
a	diagnosis	of	SSTI	(rather	than	flucloxacillin	prescribing),	of	12·8%.3	However,	432	
the	diagnosis	of	bacterial	infection	is	not	always	straightforward	in	primary	care,	433	
and	prescribing	a	subsequent	antibiotic	is	not	necessarily	an	indication	that	the	434	
first	antibiotic	‘failed’.	For	example,	in	our	study	subsequent	antibiotic	435	
prescribing	may	have	been	for	another	condition	or	for	colonised	skin	ulcers,	436	
eczema	flares	or	hidradenitis	suppurativa,	and	may	not	be	an	indication	that	the	437	
first	antibiotic	‘failed’.	Nevertheless,	most	antibiotic	treatment	is	intended	to	be	438	
delivered	as	a	single	course,	and	therefore	our	finding	that	17·5%	received	a	439	
subsequent	course	is	of	concern.	We	found	that	being	prescribed	a	higher	dose	of	440	
flucloxacillin	increased	the	risk	of	being	prescribed	a	subsequent	antibiotic.	This	441	
probably	represents	confounding	by	indication,	with	those	having	more	severe	442	
infections	prescribed	higher	doses	and	thus	being	more	likely	to	re-consult.	Our	443	
finding	that	children	were	less	likely	(than	adults)	to	require	a	subsequent	444	
course,	despite	often	receiving	doses	that	are	below	guideline	recommendations,	445	
suggests	that	either	dosing	guidelines	need	revisiting	or	that	many	of	these	446	
initial	prescriptions	were	unnecessary.	Resistance	to	flucloxacillin	may	be	a	447	
reason	for	the	high	rate	of	further	prescriptions,	however	MRSA	prevalence	in	448	
commensal	organisms	in	the	community	is	relatively	low	in	the	UK.18	Diagnosis	449	
of	skin	infections	has	been	shown	to	be	problematic,13	and	mis-diagnosis	may	450	
also	be	a	contributing	factor.	451	
	452	
Seasonal	variation	has	been	previously	described	in	both	the	incidence	of	453	
impetigo20	and	hospital	admissions	for	non-necrotizing	cellulitis,21	and	Fleming	454	
and	colleagues	have	previously	shown	increased	flucloxacillin	prescribing	in	the	455	
third	quarter.7	However,	we	have	provided	a	more	detailed	analysis	and	been	456	
able	to	show	that	prescribing	peaks	in	July	and	that	seasonal	variation	is	more	457	
pronounced	for	some	diagnostic	categories	(infected	traumatic	lesions,	cellulitis	458	
and	non-specific	SSTI)	than	for	others	(impetigo	and	‘other	SSTI’).		459	
	460	
Cellulitis	is	the	main	serious	SSTI	and	therefore	it	is	not	surprising	that	cellulitis	461	
and	abscess	was	identified	as	the	most	common	diagnostic	category.	However,	462	
we	found	that	many	prescriptions	were	associated	with	other	codes	or	not	463	
associated	with	any	useful	code.	A	previous	study	of	indications	for	antibiotic	464	
prescribing	in	primary	care	identified	‘skin’,	‘other’,	‘abscess/boil’	and	‘impetigo’	465	
as	the	most	common	categories.1	It	is	difficult	to	make	direct	comparisons	due	to	466	
differences	in	the	way	conditions	were	classified,	but	we	found	that	‘boils’	and	467	
‘impetigo’	were	uncommon	diagnoses	associated	with	flucloxacillin	prescribing,	468	
and	that	‘other’	conditions	and	no	relevant	code	were	the	most	common	469	
categories.	Part	of	the	explanation	for	the	differences	lies	in	the	complexities	of	470	
Read	coding;	some	Read	codes	are	for	‘Cellulitis	or	abscess’	and	therefore,	as	it	471	
was	impossible	to	disentangle	these	diagnoses	completely,	we	grouped	them	472	
together.	There	is	clearly	an	important	need	to	improve	coding	in	primary	care	473	
medical	records.	NHS	funders	should	work	closely	with	electronic	medical	474	
record	suppliers	to	optimise	their	systems	in	order	to	make	it	easier	to	apply	475	
codes	accurately,	and	primary	care	staff	should	be	trained	and	incentivised	to	476	
code	more	accurately.	Finally,	the	UK	should	consider	moving	away	from	the	477	
Read	code	system,	which	is	repetitive	and	allows	for	vague	and	unhelpful	coding,	478	
to	a	more	standardised	and	universally	accepted	coding	system	such	as	the	479	
International	Classification	of	Primary	Care.	480	
	481	
Previous	research	has	highlighted	higher	levels	of	antibiotic	prescribing	482	
(particularly	flucloxacillin)	in	patients	identified	as	having	chronic	wounds.22	483	
While	we	did	not	specifically	identify	this	group,	codes	associated	with	484	
wounds/dressings	accounted	for	only	3·6%	of	prescribing	in	our	study,	485	
suggesting	that	while	high	levels	of	prescribing	may	have	important	implications	486	
for	the	individuals	involved,	chronic	wounds	do	not	seem	to	be	a	major	487	
contributor	to	overall	levels	of	acute	prescribing	for	flucloxacillin.	488	
	489	
Staphylococcus	aureus	and	Group	A	Streptococci	are	both	important	causes	of	490	
skin	infections,	and	guidelines	sometimes	recommend	using	flucloxacillin	to	491	
cover	the	Staphylococcus	and	penicillin	V	for	the	Streptococci.11	We	found	that	492	
co-prescribing	occurred	in	only	a	small	minority	of	consultations,	and	we	are	not	493	
aware	of	any	other	evidence	on	the	frequency	of	co-prescribing	penicillin	V	with	494	
flucloxacillin.	495	
	496	
Our	findings	highlight	a	need	to	understand	better	the	reasons	for	the	on	going	497	
increase	in	prescribing	of	flucloxacillin	in	UK	primary	care.	Although	we	498	
identified	older	age	and	diagnosis	of	cellulitis,	and	not	a	younger	age	and	499	
diagnosis	of	impetigo,	as	areas	to	focus	on,	problems	with	diagnostic	coding	500	
limited	our	ability	to	draw	firm	conclusions.	Prospective	observational	studies	or	501	
analyses	of	routine	data	where	the	diagnosis	is	confirmed	(by	contacting	502	
participating	clinicians	or	through	an	analysis	of	the	‘free	text’)	could	provide	503	
greater	clarity.	It	is	unclear	how	generalizable	our	results	are	to	other	settings	504	
(secondary	care	and	other	countries),	and	there	is	limited	data	on	MRSA	.	There	505	
is	also	a	need	for	trials	to	explore	the	optimal	use	of	oral	antibiotics	in	the	506	
management	of	SSTIs,	including	optimal	dose	and	duration	and	the	role	of	co-507	
prescription	of	penicillin	V,	or	other	antibiotics,	with	flucloxacillin.	Finally,	there	508	
is	a	need	to	understand	why	the	prescribing	of	further	antibiotics	within	four	509	
weeks	of	an	initial	prescription	of	flucloxacillin	is	so	prevalent.	Sub-optimal	510	
dosing	or	incorrect	choice	of	antibiotic	may	play	a	role,	but	mis-diagnosis	of	511	
other	inflammatory	skin	conditions	as	infection	could	also	be	a	reason.	512	
Therefore,	there	is	a	need	to	evaluate	(and	seek	to	improve)	the	diagnostic	513	
accuracy	of	the	clinical	diagnosis	of	cellulitis	in	primary	care.	514	
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Tables	603	
Table	1	–	Average	monthly	flucloxacillin	prescribing	rate	by	year	604	
Year	 Prescribing	rate	(prescriptions	
per	1,000	PY)*	
2004	 4.74	
2005	 4.81	
2006	 5.12	
2007	 5.17	
2008	 5.33	
2009	 5.44	
2010	 5.54	
2011	 5.72	
2012	 5.83	
2013	 5.74	
*	Age-standardised	to	2004	population	of	
England	and	Wales	
	605	
	 	606	
Table	2	–	Linear	regression	of	flucloxacillin	prescribing	rate	on	study	607	
month	controlling	for	month	of	year	608	
Variable	 Coefficient	(95%	CI)	 p	
Study	month	 0·01	(0·01,	0·01)	 0·000	
Month	of	the	year	(Ref:	
December)	
1	 Ref	
January	 0·18	(0·08,	0·44)	 0·175	
February	 0·38	(0·12,	0·64)	 0·004	
March	 0·53	(0·27,	0·79)	 0·000	
April	 0·41	(0·15,	0·67)	 0·002	
May	 0·61	(0·35,	0·87)	 0·000	
June	 1·34	(1·08,	1·59)	 0·000	
July	 1·61	(1·35,	1·87)	 0·000	
August	 1·34	(1·08,	1·60)	 0·000	
September	 1·26	(1.00,	1·52)	 0·000	
October	 0·73	(0·47,	0·99)	 0·000	
November	 0·55	(0·29,	0·81)	 0·000	
	 	 	
Constant	 -1·45	(-2·36,	-0·55)	 0·002	
	609	
	 	610	
	611	
	612	
Table	3	–	Total	amount	of	flucloxacillin	prescribed	by	age	group	(0-10	613	
years)	614	
Amount	
prescribed	
1-1250g	
	
n	(row	%)	
1251-
2500g	
n	(row	%)	
2501-
5000g	
n	(row	%)	
5001-
7000g	
n	(row	%)	
>7000g	
	
n	(row	%)	
Total	
	
n		
Equivalent	to	
(upper	band)	
62·5mg	4	
times	a	
day	for	5	
days	
125mg	4	
times	a	
day	for	5	
days	
250mg	4	
times	a	
day	for	5	
days	
250mg	4	
times	a	
day	for	7	
days	
>	250mg	4	
times	a	
day	for	7	
days	
	
Age	band	
0-1	 1,537	
(3·3%)	
40,661	
(86·3%)	
4,661	
(9·9%)	
69	
(0·2%)	
173	
(0·4%)	
47,101		
2-3	 237	
(0·3%)	
54,985	
(79·7%)	
12,840	
(18·6%)	
361	
(0·5%)	
595	
(0·9%)	
69,018			
4-5	 38	
(0·1%)	
47,622	
(72·6%)	
15,809	
(24·1%)	
894	
(1·4%)	
1,237	
(1·9%)	
65,600		
6-7	 34	
(0·1%)	
32,605	
(56·9%)	
20,254	
(35·4%)	
2,177	
(3·8%)	
2,206	
(3·9%)	
57,276		
8-10	 69	
(0·1%)	
25,918	
(33·9%)	
36,003	
(47·0%)	
9,682	
(12·7%)	
4,866	
(6·4%)	
76,538		
Total	 1,915	
(0·6%)	
201,791	
(64·0%)	
89,567	
(28·4%)	
13,183	
(4·2%)	
9,077	
(2·9%)	
315,533		
	615	
	 	616	
Table	4	–Diagnostic	classifications	recorded	with	flucloxacillin	prescribing	617	
Coding	Category	–	
N	(%)	
Main	sub-categories	(up	to	3)	 No.	(%	of	total)	
No	relevant	code	-	
774,919	
(25·6)	
‘Patient	reviewed’	 106,458	(3·5)	
‘Telephone	encounter’		 80,530	(2·7)	
‘Had	a	chat	to	patient’		 34,691	(1·1)	
Cellulitis	or	abscess	
-	301,805	(10·0)	
Cellulitis	 189,359	(6·2)	
Cellulitis	or	abscess	 59,802	(2·0)	
Abscess	 52,644	(1·7)	
Secondary	
infection	of	skin	
conditions	/	
lesions	-	302,974	
(10·0)	
Infected	eczema	/	dermatitis		 		103,851	(3·4)	
Cysts	,	warts,	naevi,	blisters	and	
other	skin	lesions		
69,688	(2·3)	
Infected	cyst	/	blister	 62,697	(2·1)	
Non-specific	SSTI	-	
293,641	(9·7)	
SSTI	NOS		 192,650	(6·4)	
Rash	/	skin	symptoms	 70,106	(2·3)	
Traumatic	lesion	/	
wound	-	275,662	
(9·1)	
Wound	/	dressing		 109,074	(3·6)	
Insect	bite	 96,227	(3·2)	
Post-operative	infection	 40,137	(1·3)	
Infected	digit	/	nail	
-	261,499	(8·6)	
Ingrowing	nail		 97,173	(3·2)	
Paronychia		 87,798	(2·9)	
Infection	toe	/	finger	 76,528	(2·5)	
No	code	-	244,021	
(8·1)	
	 244,021	(8·1)	
Infection	classified	
by	site	(other	than	
digits)	-	223,782	
(7·4)	
Breast	infection	 40,484	(1·3)	
Otitis	externa	 37,615	(1·2)	
Eye	/	eyelid	infection	 34,073	(1·1)	
Boils	/	folliculitis	-	
170,281	(5·6)	
Furuncle	/	carbuncle	 109,287	(3·6)	
Folliculitis	 60,994	(2·0)	
Impetigo	-	126,638	
(4·2)	
Impetigo	 126,638	(4·2)	
Other	skin	
infection	-	49,026	
(1·6)	
Superficial	phlebitis		 14,849	(0·5)	
Pustules	/	septic	spots		 13,781	(0·5)	
Superficial	lump	/	swelling	 7,890	(0·3)	
Other	infection	-	
7,768	(0·3)	
Respiratory	 6,784	(0·2)	
Urinary	 590	(<0·1)	
Osteomyelitis	 394	(<0·1)	
Total:	3,032,016	
(100)	
	 	
	618	
	 	619	
Table	5	-	Number	of	prescriptions	per	episode	of	care	620	
Number	of	prescriptions	
in	episode	
Number	of	episodes	 Proportion	of	episodes	
(%)	
1	 2,279,574	 82·4	
2	 359,477	 13·0	
3	 83,013	 3·0	
4+	 43,942	 1·6	
Total	 2,766,006	 100	
	621	
	 	622	
Table	6	–	Factors	associated	with	a	subsequent	antibiotic	prescription	623	
within	28	days	624	
	 Odds	Ratio	 95%	CI	-	Lower	 95%	CI	-	Upper	
Age	band	 	 	 	
0-4	 1·27	 1·24	 1·30	
5-9	 ·91	 ·88	 ·93	
10-19	 ·93	 ·92	 ·94	
20-59	(REF)	 1	 	 	
60-69	 1·37	 1·35	 1·38	
70-79	 1·57	 1·55	 1·58	
80+	 1·67	 1·66	 1·69	
Gender	 	 	 	
Male	(REF)	 1	 	 	
Female	 1·04	 1·03	 1·04	
Diagnostic	category	 	 	 	
No	SSTI	code	(REF)	 1	 	 	
Cellulitis	or	abscess	 1·32	 1·31	 1·34	
Impetigo	 1·08	 1·06	 1·10	
Boils	/	folliculitis	 ·90	 ·89	 ·91	
Infected	digit	/	nail	 ·95	 ·94	 ·96	
Infection	classified	by	
site	(other	than	digits)	
·88	 ·87	 ·89	
Traumatic	lesion	/	
wound	
·91	 ·89	 ·92	
Secondary	infection	of	
skin	lesion	
1·00	 ·99	 1·01	
Non-specific	SSTI	 ·95	 ·94	 ·96	
Other	skin	infection	 ·99	 ·96	 1·01	
No	code	 1·28	 1·27	 1·30	
Dose	 	 	 	
500mg	tablets	 1·29	 1·27	 1·31	
250mg	tablets	(REF)	 1	 	 	
Suspension	 1·00	 ·97	 1·02	
	 	 	 	
Year	(continuous)	 1·00	 1·00	 1·00	
Dose	x	year	
interaction	
	 	 	
500mg	 1·00	 1·00	 1·00	
250mg	(REF)	 1	 	 	
Liquid	 1·01	 1·00	 1·01	
	 	 	 	
Constant	 ·17	 ·15	 ·16	
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Figure	3	–	Flucloxacillin	prescribing	by	gender	for	three	age	bands:	2004-634	
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Figure	4	–	Flucloxacillin	prescribing	by	formulation:	2004-2013	639	
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